GRTX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 mai 2024 @ 22:00):

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer...

Stats
Dagens volum	586 611
Gjennomsnittsvolum	2.06M
Markedsverdi	10.32M
EPS	$0 ( 2024-03-25 )
Neste inntjeningsdato	( $0 ) 2024-06-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.140
ATR14	$0.00100 (0.53%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Schneid Yair	Buy	99 371	Common Stock
2024-04-19	Schneid Yair	Buy	215	Common Stock
2024-04-19	Schneid Yair	Buy	314	Common Stock
2024-04-19	Schneid Yair	Buy	100	Common Stock
2024-04-18	Schneid Yair	Buy	74 202	Common Stock

INSIDER POWER
99.83
Last 95 transactions
Buy: 7 344 028 \| Sell: 846 527

Volum Korrelasjon

Lang: -0.19 (neutral)

Kort: 0.82 (strong)

Signal:(51.211) Same movement expected

Galera Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner
LIAN	0.848
IMAB	0.843
MEUSW	0.842
PXLW	0.841
ADXN	0.839
LEGO	0.833
FORA	0.828
VYGR	0.814

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Galera Therapeutics Inc Korrelasjon - Valuta/Råvare

0.00
( neutral )

-0.08
( neutral )

0.00
( neutral )

-0.07
( neutral )

Galera Therapeutics Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-259 000 (0.00 %)
EPS:	$-1.330

FY	2023
Omsetning:	$0
Bruttogevinst:	$-259 000 (0.00 %)
EPS:	$-1.330

FY	2022
Omsetning:	$0
Bruttogevinst:	$-114 000 (0.00 %)
EPS:	$-2.30

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-3.06

Financial Reports:

No articles found.

Galera Therapeutics Inc

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.